[1] Hanson GK, Robertson AK, Soderberg-Naucler C.Inflammation and atherosclerosis[J]. Annu Rev Pathol, 2006, 1:297-329. [2] Wang Q.Molecular genetics of coronary artery disease[J]. Curr Opin Cardiol, 2005, 20(3):182-188. [3] Spanbroek R, Grabner R, Lotzer K, et al.Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis[J]. Proc Natl Acad Sci USA, 2003, 100(3):1238-1243. [4] Merched AJ, Ko K, Gotlinger KH, et al.Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators[J]. FASEB J, 2008, 22(10):3595-3606. [5] Hoshiko S, Radmark O, Samuelsson B.Characterization of the human 5-lipoxygenase gene promoter[J]. Proc Natl Acad Sci USA, 1990, 87(23):9073-9077. [6] Dwyer JH, Hooman A, Dwyer KM, et al.Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis[J]. N Engl J Med, 2004, 350(1):29-37. [7] Bennett CF, Chiang MY, Monia BP, et al.Regulation of 5-lipoxygenase and 5-lipoxygenase activating protein expression in HL-60 cells[J]. Biochem.J, 1993,289:33-39. [8] Dixon RAF, Diehl RE, Opas E, et al.Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis[J]. Nature, 1990, 343(6225):282-284. [9] Vickers PJ, O扤eill GP, Mancini JA, et al. Cross-species comparison of 5-lipoxygenase activating protein[J]. Mol.Pharmacol, 1992, 42:1014-1029. [10] 刘峻豪, 孙凯, 白永怿, 等. Notch3基因多态、MTHFR基因多态和ALOX5AP基因多态的多位点联合交互作用显著增加血栓性脑卒中的风险[J]. 中国分子心脏病学杂志, 2008, 8(6):328-332. [11] Qiu H, Johansson AS, Sjostrom M, et al.Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4[J]. Proc Natl Acad Sci USA, 2006, 103(18):6913-6918. [12] Mehrabian M, Wong J, Wang X, et al.Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia[J]. Circ Res, 2001, 89(2):125-130. [13] 张梅英, 吴红联, 杨葳, 等. 5-脂氧化酶转基因小鼠模型的制备[J]. 中国实验动物学报, 2010, 18(1):60-64. [14] Mehrabian M, Allayee H, Wong J, et al.Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice[J]. Circ Res, 2002, 91(2):120-126. [15] 李丽芳, 李晓霞, 滕晓云, 等. 5-脂氧化酶、白三烯在动脉粥样硬化大鼠主动脉中的表达[J]. 宁夏医学杂志, 2010, 3(12):1125-1127. [16] 王崇泽, 曲毅, 方宁远, 等. 5 脂氧合酶在自发性高血压大鼠脑血管中的表达[J]. 中华高血压杂志, 2008, 16(10):915-918. [17] Vidal C, Gomez-Hernandez A, Sanchez-Galan E, et al.Licofelone, a balanced Inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis[J]. JPET, 2007, 320(1):108-116. [18] Ghosh S, Novak EM, Innis SM, et al.Cardiac proinflammatory pathways are altered with different dietary n-6 linoleic to n-3 α-linolenic acid ratios in normal, fat-fed pigs[J]. Am J Physiol Heat Circ Physiol 2007, 293:H2919-H2927. [19] Tardif JC, L'Allier PL, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291(Atreleuton) in patients with recent acute coronary syndrome[J]. Cric Cardiovasc Imaging, 2010, 3:298-307. [20] Motoyama S, Sarai M, Harigaya H, et al.Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome[J]. J Am Coll Cardiol, 2009, 54:49-57. [21] Cipollone F, Mezzetti A, Fazia ML, et al.Association between 5-lipoxygenase expression and plaque instability in human[J]. Arterioscler Thromb VAsc Biol, 2005, 25(8):1665-1670. [22] Zhao L, Moos MP, Grabner R, et al.The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm[J]. Nat Med, 2004, 10(9):966-973. [23] 肖尧. MEF2A和ALOX5基因多态性与冠状动脉粥样硬化性心脏病的相关性研究[D]. 北京. 中国协和医科大学, 2006. [24] Tsai MY.Interaction of dietary fatty acids with 5-lipoxygenase,ALOX5 activating protein with subclinical markers of coronary artery disease[A]. 5th Biologie Prospective Santorini Conference[C], Pers Med, 2011:227-242. [25] Lorrain DS, Bain G, Correa LD, et al.Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation[J]. Eur J Pharmacol, 2010, 640(1-3):211-218. [26] Back M, Sultan A, Hansson GK.5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation[J]. Circ Res, 2007, 100:946-949. [27] Jawien J, Gajda M, Rudling M, et al.Inhibition of five lipoxygenase activating protein(FLAP) by MK-886 decreases atherosclerosis in apoE/lDLR-double knockout mice[J]. Eur J Clin Invest, 2006, 36(3):141-146. [28] 徐晓伟, 盛文利, 刘琳. Pde4d和Alox5ap的mRNA水平与高血压性脑卒中和高血压病相关性的动物实验研究[J]. 中华医学遗传学杂志, 2007, 24(5):491-494. [29] Zhou GY, Ge S, Liu DZ, et al.Atorvastatin Reduces Plaque Vulnerability in an Atherosclerotic Rabbit Model by Altering the 5-Lipoxygenase Pathway[J]. Cardiology, 2010, 115:221-228. [30] Xu ZY, Azordegan N, Zhao ZH, et al.Pro-atherogenic effects of probucol in apo E-KO mice may be mediated through alterations in immune system: Parallel alteration in gene expression in the aorta and liver[J]. Atherosclerosis, 2009, 206(2):427-433. [31] Helgadottir A, Manolescu A, Thorleifsson G, et al.The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke[J]. Nat Genet, 2004, 36(3):233-239. [32] Koch W, Hoppmann P, Mueller JC, et al.No association of polymorphisms in the gene encoding 5-lipoxygenase activating protein and myocardial infarction in a large central European population[J]. Genet Med, 2007, 9(2):123-129. [33] Girelli D, Martinelli N, Trabetti E, et al.ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study[J]. Eur J Hun Genet, 2007, 15(9):959-966. [34] Tsai AK, Li N, Hanson NQ, et al.Associations of genetic polymorphisms of arachidonate 5-lipoxygenase-activating protein with risk of coronary artery disease in a European-American population[J]. Atherosclerosis, 2009(207):487-491. [35] 张春燕, 郭玮, 吴炯, 等. 五脂氧化酶激活蛋白基因多态性及冠心病易患风险[J]. 中国临床医学, 2010, 17(5):631-634. [36] Huang H, Zeng Z, Li J, et al.Variants of arachidonate 5-lipoxygenase-activating protein(ALOX5AP) gene and risk of coronary heart disease: a meta-analysis[J]. Arch Med Res, 2010, 41(8):634-641. |